The current tuberculosis (TB) predicament poses numerous challenges and therefore every
incremental scientific work and all positive socio-political engagements, are steps taken in …

Mycobacterium tuberculosis (Mtb) is one of the most important infectious agents worldwide
and causes more than 1.5 million deaths annually. To make matters worse, the drug …

ClpP is a highly conserved serine protease that is a critical enzyme in maintaining protein
homeostasis and is an important drug target in pathogenic bacteria and various cancers. In …

The ring-forming AAA+ hexamer ClpC1 associates with the peptidase ClpP1P2 to form a
central ATP-driven protease in Mycobacterium tuberculosis (Mtb). ClpC1 is essential for Mtb …

The rise of multi-and extensively drug-resistant Mycobacterium tuberculosis (M. tb) strains
and co-infection with human immunodeficiency virus has escalated the need for new anti-M …

The unfoldase ClpC1 is one of the most exciting drug targets against tuberculosis. This
AAA+ unfoldase works in cooperation with the ClpP1P2 protease and is the target of at least …

Antimicrobial resistance is a global health threat that requires the development of new
treatment concepts. These should not only overcome existing resistance but be designed to …

Antibiotics form our frontline therapy against disease-causing bacteria. Unfortunately,
antibiotic resistance is becoming more common, threatening a future where these …

Mycobacterium tuberculosis Clp proteases are targeted by several antitubercular
compounds, including cyclomarin A (CymA). CymA exerts its toxicity by binding to AAA+ …

In the post-antibiotic era, the rapid development of antibiotic resistance and the shortage of
available antibiotics are triggering a new health-care crisis. The discovery of novel and …